Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorFifth Affiliated Hospital, Sun Yat-Sen University

About this trial

A large number of clinical studies have shown that oral administration, external application or enema of Chinese medicine can promote the recovery of gastrointestinal function and the absorption of pancreatic inflammation. The aims of the study is to explore the application of Dachaihu Decoction Compound (DDC)and Rhubarb Single Medicine (RSM) in the Treatment of Acute Pancreatitis.

Eligibility criteria

Qualifiers

Age from 18 to 65 years old

Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset

Consent of the subjects, who sign the informed consent form

Disqualifiers

Women who are pregnant or breastfeeding

Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc.

Patients with a history of severe heart, liver, kidney and other important organ diseases

Patients with mental illness and malignant tumors

Trial design

Treatments tested in this trial

  • Dachaihu decoction compound
  • Rhubarb single medicine
  • Regular therapies

Treatment groups

306 Participants
are divided into 3 treatment groups

Locations

This trial has no locations